The 14 most recent market catalysts affecting $CRSP, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 9, 2026
Corporate Catalyst
Bullish
Impact 85
CRISPR Therapeutics Presents Positive Phase 1b Clinical Data for CTX310
CRISPR Therapeutics presented new Phase 1b data for CTX310, an in vivo gene editing therapy for severe hypertriglyceridemia (sHTG). The data showed substantial reductions in ANGPTL…
Nov 8, 2026
Corporate Catalyst
Neutral
Impact 75
CRISPR Therapeutics Provides Update on Zugocabtagene Geleucel (Zugo-cel) in Refractory Rheumatologic Autoimmune Diseases
CRISPR Therapeutics provided an update on its Phase 1 basket trial for zugo-cel, an allogeneic CAR-T therapy for autoimmune diseases. The filing highlights strong clinical response…
Nov 4, 2026
Corporate Catalyst
Neutral
Impact 65
CRISPR Therapeutics to Present Clinical Data for Zugo-cel at 68th ASH Annual Meeting
CRISPR Therapeutics is announcing its plan to present clinical data for zugo-cel, an allogeneic CAR T cell therapy, at the 68th ASH Annual Meeting in December 2026. This is signifi…
Nov 2, 2026
Corporate Catalyst
Neutral
Impact 65
CRISPR Therapeutics Appoints Sivakesava Sakhamuri as Chief Technical Officer
CRISPR Therapeutics (CRSP) has appointed Dr. Sivakesava Sakhamuri as Chief Technical Officer, a move that signals the company's focus on strengthening its manufacturing and technic…
Oct 23, 2026
Corporate Catalyst
Bearish
Impact 75
Resignation of CRISPR Therapeutics CFO
CRISPR Therapeutics AG reported the resignation of its Chief Financial Officer, a key executive departure that signifies a change in the company's core management. This event is pa…
Oct 19, 2026
Corporate Catalyst
Neutral
Impact 75
CRISPR Therapeutics Appoints A. J. Silver CFO, Effective Immediately, Succeeding Raju Prasad
CRISPR Therapeutics (CRSP) announced that its CFO, Raju Prasad, is stepping down to pursue other opportunities, effective immediately. A.J. Silver, the company's Senior Vice Presid…
Oct 15, 2026
Corporate Catalyst
Neutral
Impact 55
UBS Initiates Coverage On CRISPR Therapeutics with Neutral Rating, Announces Price Target of $52
UBS analyst Joon Lee has initiated coverage on CRISPR Therapeutics (CRSP), assigning a 'Neutral' rating and a $52 price target. This event is significant for CRSP as new analyst co…
Oct 8, 2026
Corporate Catalyst
Neutral
Impact 75
CRISPR Therapeutics To Present Phase 1b Data For CTX310 In Severe Hypertriglyceridemia In Late-Breaking AHA Presentation On November 9
The presentation of Phase 1b data for CTX310 is a critical milestone for CRISPR Therapeutics. Positive results would significantly de-risk the program, potentially accelerating its…
Sep 23, 2026
Corporate Catalyst
Bearish
Impact 85
CRISPR Therapeutics shares are trading lower after reports that Anthropic's Biolab has discovered a new enzyme system that resembles the Crispr gene editing tool.
This headline represents a significant corporate catalyst for CRISPR Therapeutics (CRSP) and the broader gene-editing sector. The discovery of a new, similar enzyme system by Anthr…
Aug 31, 2026
Corporate Catalyst
Neutral
Impact 55
Needham Reiterates Buy on CRISPR Therapeutics, Maintains $82 Price Target
Needham analyst Gil Blum reiterated a 'Buy' rating and maintained an $82 price target for CRISPR Therapeutics. This action signals continued confidence from a prominent analyst in …
Aug 28, 2026
Corporate Catalyst
Bullish
Impact 75
CRISPR Therapeutics Data From Its Phase 1 Clinical Study Of CTX Shows 79% Mean Reductions From Baseline For ANGPTL3, 48% Maximum For Triglycerides
CRISPR Therapeutics released extended follow-up data from its Phase 1a clinical trial for CTX310, an investigational gene-editing therapy. The data demonstrated deep and durable re…
Aug 25, 2026
Corporate Catalyst
Bullish
Impact 75
CRISPR Therapeutics shares are trading higher after Citizens reiterated its Market Outperform rating and maintained a $80 price target.
This headline indicates a positive corporate catalyst for CRISPR Therapeutics. The reiteration of an 'Outperform' rating and a substantial price target from a reputable financial i…
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 55
Citigroup Maintains Buy on CRISPR Therapeutics, Raises Price Target to $88
Citigroup's analyst Yigal Nochomovitz maintained a 'Buy' rating on CRISPR Therapeutics and raised the price target from $82 to $88. This action signals continued bullish sentiment …
Aug 3, 2026
Corporate Catalyst
Bullish
Impact 92
CRISPR Therapeutics Q2 EPS $(0.94) Beats $(1.17) Estimate, Sales $10.181M Beat $6.789M Estimate
CRISPR Therapeutics announced Q2 earnings that significantly surpassed analyst expectations, with a loss of $(0.94) per share against an estimated $(1.17). More notably, sales reac…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.